trial

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

NCTId NCT05227690
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 385 (actual)
Sponsored by AbbVie
Primary completion 2024-08-23
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
385 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2022-06-30
Primary completion
2024-08-23
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Emraclidine

Sponsors

AbbVieLead Sponsor

Sites

25 total
Little Rock, United StatesAnaheim, United StatesGarden Grove, United StatesLemon Grove, United StatesMontclair, United StatesRiverside, United StatesSan Diego, United StatesHialeah, United StatesHollywood, United StatesMangonia Park, United StatesOakland Park, United StatesAtlanta, United States

Linked catalysts

1
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schi — primary completion2024-08-23

Facts & assertions

4 sourced
Enrollment
385
Phase
PHASE2
Primary Completion Date
2024-08-23
Status
COMPLETED
relationships
The graph out of here
drug
Emraclidine
drug
lead_sponsor
AbbVie
company
indication
Schizophrenia
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication